The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...
The company, launched with help from ex-Novartis executives, is targeting glutamate signaling in the brain to help treat ...
SAN FRANCISCO and SUZHOU, China, March 23, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that ...
Following the conclusion of the 2024-25 Kansas high school basketball season, coaches from around the state took the time to ...
Kingston High School has released its highest honor (94.5 to 100), high honor (89.5 to 94.49), and honor (84.50-89.49) rolls ...
Zacks Investment Research on MSN3d
J&J's Tremfya Gets FDA Nod for 2nd IBD Condition Crohn's DiseaseJohnson & Johnson JNJ announced that the FDA has granted approval to its key drug, Tremfya, for its second inflammatory bowel ...
Clinical hold lifted for late stage cadisegliatin program for diabetesCATT1 Phase 3 trial in patients with type 1 diabetes (T1D) expected to ...
Clinical hold lifted for late stage cadisegliatin program for diabetes CATT1 Phase 3 trial in patients with type 1 diabetes (T1D) expected to resume Q2 2025 Strengthens commercial leadership with appo ...
The two simultaneous Incyte trials in HS saw more than 40% of patients on povorcitinib achieving a clinical response.
A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback